Market Overview

Merck Returns Rights for Vernakalant to Cardiome

Share:
Related MRK
Expert Explains How To Play Merck In 2 Charts
Credit Suisse: We Prefer Pfizer, Bristol Over Pharma Peers
Related CRME
Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement
Earnings Scheduled For March 12, 2015

Cardiome Pharma Corp. (Nasdaq: CRME) (TSX:COM) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Merck will return the global marketing and development rights for both the intravenous (IV) and oral formulations for vernakalant to Cardiome.

Vernakalant IV is marketed, in certain countries, under the brand name BRINAVESS.^TM BRINAVESS was approved in the European Union on September 1, 2010 for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less.  Vernakalant IV is not approved for use in the United States or Canada.

Posted-In: News FDA

 

Related Articles (CRME + MRK)

Around the Web, We're Loving...

Get Benzinga's Newsletters